United Therapeutics Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

United Therapeutics hat ein Gesamteigenkapital von $6.1B und eine Gesamtverschuldung von $400.0M, wodurch sich der Verschuldungsgrad auf 6.6% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen $7.1B bzw. $1.0B. United Therapeutics Das EBIT des Unternehmens beträgt $1.3B, so dass der Zinsdeckungsgrad -8.9 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von $3.3B.

Wichtige Informationen

6.6%

Verhältnis von Schulden zu Eigenkapital

US$400.00m

Verschuldung

Zinsdeckungsgrad-8.9x
BargeldUS$3.33b
EigenkapitalUS$6.10b
GesamtverbindlichkeitenUS$1.02b
GesamtvermögenUS$7.12b

Jüngste Berichte zur Finanzlage

Recent updates

United Therapeutics: One To Believe In Despite Competitive Threats

Nov 14

Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

Oct 18
Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price

Sep 27
Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price

United Therapeutics: Economics Support Compounding Ability

Aug 20

With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

Jul 26
With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

Jul 04
United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market

Jun 13
United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market

United Therapeutics: Exciting Company With A Big Problem

Jun 02

We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease

Apr 05
We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease

United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects

Mar 20

Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?

Mar 15
Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?

Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings

Jan 02
Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings

United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

Dec 08
United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

Nov 16
Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

Sep 04
United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

Aug 07
Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

May 22
United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?

Apr 25
Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?

We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease

Feb 06
We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease

With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

Jan 16
With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

Oct 20
Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

United Therapeutics: Ability To Expand Tyvaso To Large IPF Market

Aug 24

Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?

Aug 04
Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: UTHRDie kurzfristigen Aktiva des Unternehmens ($4.0B) übersteigen seine kurzfristigen Passiva ($873.4M).

Langfristige Verbindlichkeiten: UTHRDie kurzfristigen Vermögenswerte des Unternehmens ($4.0B) übersteigen seine langfristigen Verbindlichkeiten ($148.8M).


Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: UTHR über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: UTHR Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 36.8% auf 6.6% zurückgegangen.

Schuldendeckung: UTHRDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (284.2%).

Zinsdeckung: UTHR mehr Zinsen einnimmt als er zahlt, so dass die Deckung der Zinszahlungen kein Problem darstellt.


Bilanz


Entdecken Sie finanziell stabile Unternehmen